S.No,Protocols_Id,Protocol_search,STATUS,ACTUAL_FPFV,,ACTUAL_FPLV,ACTUAL_LPFV,ACTUAL_LPLV,ACTUAL_PRI_ENDPT_LPLV,ADDL_PRODUCTS,BA_BE,BLINDED_FLG,BM_FLG,BUDGET_OFFICE,CLINOPS_STUDY_LEAD,DRUG_SAFETY_SPEC,DRUG_SAFETY_SPEC_EMAIL,DUS_FLAG,EA_IPU,EPI_FLAG,EST_FPFV,EST_FPLV,EST_LPFV,EST_LPLV,EST_PRI_ENDPT_LPLV,EUDRACT_NUM,FINAL_CSR_DT,FIRST_SITE_ACTIVE,FIRST_SUBJ_ENROLLED,HV_FLAG,INDICATION,LTFU_LPLV,NICKNAME,NONGILEAD_IMP,NUM_Planned_Sites,NUM_Planned_Subjects,NUM_SUBJ_ENRL,PASS,PHASE,PK_FLG,PRIMARY_TEAM_MEMBER,PRODUCT,PRODUCT_CODE,PRODUCT_LINE,PROTOCOL,PROTOCOL_APPROVAL,PROTOCOL_CREATED,PROTOCOL_FINAL_SYNOPSIS_DT,PROTOCOL_ID,PROTOCOL_KEY_FIELD_LAST_UPDATE,PROTOCOL_SIGNOFF_DT,PROTOCOL_TYPE,REGION,REQ_REG_AUTH,SPONSOR_TYPE,TA,TITLE
1,14,Zydelig (313),Stopped,2010-03-22,,null,2015-04-28,2018-06-18,2018-06-18,Zydelig  (312),null,null,N,United States,DHOUSTON,MBAYOT,Milbert.Bayot@gilead.com,null,null,N,2010-03-22,null,2013-12-15,2018-06-18,2018-06-01,null,2018-11-15,2010-02-24,2010-03-22,N,CLL,null,null,null,20,250,202,N,P1,null,SADMIN,Zydelig  (312),312,Zydelig (IDELA),101-99,2010-01-22,2011-04-26,2010-01-22,14,2019-04-30,2010-01-22,Interventional,United States,null,Gilead Sponsored,Oncology,An Extension Study to Investigate the Safety and Durability of Clinical Activity of CAL-101 in Patients With Hematologic Malignancies
